A Non-interventional Study Evaluating Clinical Utility and Implications on Improved Patient Management of Serum Neurofilament as a Prognostic Marker for Disease Activity in Patients With Relapsing Multiple Sclerosis

NCT06551519 · clinicaltrials.gov ↗

RECRUITING

Status

700

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Sclerosis

Interventions

OTHER: ofatumumab
OTHER: DMT category 1

Sponsor

Novartis Pharmaceuticals